Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

South Korea flag South Korea · Delayed Price · Currency is KRW
30,650
-1,250 (-3.92%)
Mar 28, 2025, 3:30 PM KST
-24.32%
Market Cap 918.38B
Revenue (ttm) 8.61B
Net Income (ttm) -19.48B
Shares Out 29.96M
EPS (ttm) -653.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 214,301
Average Volume 113,635
Open 31,900
Previous Close 31,900
Day's Range 29,000 - 31,900
52-Week Range 25,450 - 42,700
Beta 0.48
RSI 57.22
Earnings Date Mar 21, 2025

About Mezzion Pharma

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea. [Read more]

Industry Pharmaceutical Preparations
Founded 2002
Employees 17
Stock Exchange KOSDAQ
Ticker Symbol 140410
Full Company Profile

Financial Performance

In 2024, Mezzion Pharma's revenue was 8.61 billion, a decrease of -72.85% compared to the previous year's 31.72 billion. Losses were -19.48 billion, 53.0% more than in 2023.

Financial Statements

News

There is no news available yet.